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Abstract

Azathioprine leads to changes in mean corpuscular volume (MCV) and
white blood cell (WBC) indices reflecting efficacy or toxicity. Understanding
the interactions between bone marrow stem cells and azathioprine could
highlight abnormal response patterns as forerunners for hematologic malignancies. This study gives a statistical description of factors influencing the
relationship between MCV and WBC in children with inflammatory bowel
disease treated with azathioprine. We found that leukopenia preceded macrocytosis. Macrocytosis is therefore not a good predictor of leukopenia. Further
studies will be necessary to determine the subgroup of patients at increased
risk of malignancies based on bone marrow response.

Introduction
Azathioprine is a prodrug purine analog thought
to exert its immunosuppressive effect through reduction in the proliferation of immune cells by
interfering with lymphocyte DNA replication and
RNA synthesis, and via downregulation of the antiapoptotic protein bcl-xL leading to premature
apoptosis.[1] Increased use of azathioprine in inflammatory bowel disease (IBD) is a consequence
of studies confirming its effect in maintenance of
remission and reduction in episodes of disease
relapse.[2]
Serious adverse effects of azathioprine include
pancreatitis, bone marrow suppression, sepsis, allergic reactions, and drug-induced hepatitis.[3] Minor
hematologic and biochemical disturbances usually necessitate dose reduction rather than drug
discontinuation. Of more recent concern is the

long-term risks of thiopurine-mediated malignancy.[4,5] It has been shown that patients with
sustained leukopenia during 6-mercaptopurine
(a metabolite of azathioprine) therapy had an increased risk of hematologic malignancies compared with control patients.[6] An emerging concern
centers on the synergistic risk of malignancy in
IBD when azathioprine or 6-mercaptopurine is
combined with biologic anti-tumor necrosis factor agents.[7] Knowledge of how azathioprine interacts with bone marrow stem cells over time is
necessary to understand the balance between the
benefits of disease control and reducing the risk
of future malignancy and other adverse events.
Azathioprine is known to lead to macrocytosis
and leukopenia.[8] Previous reports have looked
at these parameters independently. Fraser et al.[9]
showed that lower white blood cell (WBC) count,
lower neutrophil count, and independently higher
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mean corpuscular volume (MCV), but not lymphocyte count, were good predictors of achieving
and maintaining remission. Thomas et al.[10] found
that MCV could be used as a surrogate marker
for 6-thioguanine nucleotide concentration. However, their study was unable to link changes in
MCV with toxicity or to identify a significant
relationship with leukocyte counts. Glas et al.[11]
showed that lower leukocyte counts were associated with disease remission. These findings have
not been replicated in pediatric studies. There are
no studies that have defined the temporal and
dose-response relationships in hematologic parameters in children treated with azathioprine.
In order to further understand how these parameters change in children with IBD treated
with azathioprine, this study specifically aimed to
(i) statistically describe the relationship between
MCV and differential WBC count over time in
children with IBD treated with azathioprine; and
(ii) determine the effect of age, sex, diagnosis,
azathioprine dose per kg of bodyweight, thiopurine methyltransferase (TPMT) level, and additional therapy on this relationship.
Methods
Patients attending the Sheffield Children’s
Hospital (Sheffield, UK) who were prescribed
azathioprine from April 2002 to April 2007 were
identified from the hospital pharmacy database.
All patients for whom azathioprine was prescrib-

ed for a diagnosis of IBD were included. Case
notes and laboratory data were reviewed to determine patient demographics, hematologic indices,
azathioprine dosage, bodyweight, and additional
treatment modalities over predefined time intervals.
These time intervals were defined as T1 (baseline
values within 6 months prior to commencing
azathioprine), T2 (2–3 months after commencement of azathioprine), T3 (5–6 months after commencement of azathioprine), T4 (11–12 months
after commencement of azathioprine), and T5
(23–24 months after commencement of azathioprine). Where multiple values for laboratory results were present in the predefined time windows,
an average value was taken of those readings
qualifying for study inclusion.
Analysis was performed with Data Desk 5.0
statistical software (Description, Inc., Ithaca,
NY, USA). Non-parametric data were log transformed prior to regression analysis. Comparison
of summary values was via Mann-Whitney U
test for non-parametric data and paired t-test for
parametric data (changes from baseline analysis).
Trends were tested for significance by ANOVA
and more complex interactions between hematological parameters, sex, age, TPMT, and diagnosis by multiple regression analysis.
Results
A total of 113 patients under 16 years of age
were identified. Sixteen patients were excluded

Table I. Patient characteristicsa
Parameter

Crohn’s disease
(n = 52)

Ulcerative colitis
(n = 14)

Indeterminate colitis
(n = 31)

Sex
male

33

8

11

female

19

6

20

Age at diagnosis (y)

11.3 (3.7)

12.3 (3.0)

11.6 (2.6)

Dose of azathioprine initiated (mg/kg)

1.8 (0.7)

1.6 (0.6)

1.6 (0.7)

Dose of azathioprine at termination (mg/kg)

2.7 (0.7)*

2.2 (1.3)

2.3 (0.7)

Baseline MCV (fL)

74.7 (7.5)*

80.1 (5.4)

79.1 (6.2)

Baseline WBC (109/L)

10.7 (3.5)

11.1 (5.23)

11.7 (1.7)

TPMT level (pmol 6-MMP/hour/mgHb)

30.5 (8.2)

32.6 (5.2)

32.0 (10.1)

a

Values are presented as the arithmetic mean with standard deviation in parentheses.

6-MMP = 6-methylmercaptopurine; MCV = mean corpuscular volume; TPMT = thiopurine methyltransferase; WBC = white blood cell; * p < 0.05
vs other disease groups.
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Table II. Mean timepoint at each analysis (standard deviation given in parentheses)
Analysis period

Actual mean timepoint (mo)

Total number of patients
at each interval (n)

0

0

97

T2

2–3

2.55 (0.6)

97

T3

5–6

5.69 (0.8)

88

T4

11–12

11.06 (1.7)

81

T5

23–24

21.67 (4.5)

37

from the analysis on the basis of the following predefined criteria: (i) six children had incomplete or
unobtainable data for the first 3 months of commencing azathioprine; (ii) seven patients were
transferred to adult services within 3 months of
commencing azathioprine; and (iii) three children
discontinued azathioprine in the first 3 months
as a consequence of adverse reactions (two with
hyperamylasemia and one with neutropenia).
Table I summarizes the patient characteristics of
the remaining 97 patients. MCV was notably
lower in the group of patients with Crohn’s disease (74.7 fL [SD 7.5] vs 79.1 fL [SD 6.2]; p < 0.05)
when compared with the second largest group,
namely indeterminate colitis. The patient numbers at each successive time interval, which are
presented in table II, demonstrate that the majority of patients were within 12 months of commencing azathioprine therapy.
Total WBC and neutrophil count fell steadily
within the first 6 months of treatment then reached
a plateau between 6 and 24 months (figure 1). The
mean values at T3–T5 were approximately 25%
lower than the values at baseline (mean minimum
total WBC count of 7.6 · 109/L [SD 0.4] {p < 0.05}
occurring at 5.8 months [SD 0.2] {p < 0.05}). Conversely, MCV increased steadily within the first
6 months of treatment, with a plateau between 12
and 24 months (figure 2). This equates to a mean
maximum MCV of 87.9 fL (SD 1.8) [p < 0.05], which
occurred at a mean time of 9.7 months (SD 2.8)
[p < 0.05], i.e. 3.9 months after WBC count plateaued. This represented a mean percentage increase in MCV of 15% from baseline. The plateau
occurred despite a steady increase in the cumulative dose of azathioprine per kg of bodyweight
at each time interval (from 1.75 mg/kg [SD 0.75]
ª 2010 Soman et al., publisher and licensee Adis Data Information BV.

at baseline to 2.44 mg/kg [SD 0.77] at T5), as
shown in figure 3.
Ten children were macrocytic (MCV >100 fL)
at 24 months. These children were noted to have
a significantly greater MCV at baseline (80.5 fL
[SD 3.9] vs 70.5 fL [SD 4.3]; p = 0.006) than children who had normocytic red blood cells at
24 months.
The relationship between MCV and WBC
values (or change in MCV and change in WBC)
across the study period was not influenced by
age, sex, azathioprine dose per kg of bodyweight,
concomitant infliximab use, elemental diet, or
corticosteroid use being factored into a multifactorial regression. Furthermore, TPMT was
noted to be a weak predictor of the relationship
between MCV and WBC (p < 0.05; r2 = 15%) in a
multifactorial regression analysis. However, the
Lymphocyte
Neutrophil
Total WBC
12
10
Cell count (109/L)

T1

Target time interval (mo)

8
6
4
2
0
T1
(n = 97)

T2
(n = 97)

T3
(n = 88)

T4
(n = 81)

T5
(n = 37)

Time period
Fig. 1. Trend in differential white blood cell (WBC) count.
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Fig. 2. Disease-specific trends in mean corpuscular volume (MCV).

association between MCV and WBC count was
significantly strengthened by including a diagnosis of Crohn’s disease in the regression (p < 0.05;
r2 = 17%).
Discussion
This study defines a temporal relationship between WBC count and MCV. Opinion that elevated MCV could predict leukopenia secondary
to azathioprine toxicity is commonplace; however, our data do not support this notion. In fact,
since leukopenia generally precedes macrocytosis, this is unlikely to be the case. We therefore
suggest that although macrocytosis may indicate
toxicity, it is less likely to be able to predict it in a
timely manner. Since the majority of the reduction in WBC, lymphocyte, and neutrophil counts
occurs in the first 6 months, it is more likely that
regular blood monitoring in the first 6 months of
azathioprine therapy will detect drug-induced bone
marrow suppression, although this can occur at
any stage of therapy.[12] Since indices stabilize by
12 months, the frequency of monitoring can be
reduced thereafter.
ª 2010 Soman et al., publisher and licensee Adis Data Information BV.

Our findings identified that the patients who
were macrocytic at 24 months were also noted
to have an elevated MCV at baseline. There was
no clinical evidence of toxicity in these patients. It
is possible that this group had a greater baseline
MCV due to, as yet, unidentified genetic factors
or disease-related factors such as vitamin B12 or
folate deficiency. Our study did not include assessments of B12 levels or folate as potential causes of
macrocytosis. Although MCV levels reached a
plateau, they never returned to baseline, indicating a likely sustained effect of azathioprine rather than a confounding factor. If vitamin B12 or
folate deficiency were presumed to be the confounding factor, one would expect MCV to return
to baseline as the clinical status of the disease improved. This did not occur. Therefore, it is more
likely that pretreatment factors that are, as yet,
unknown may predispose some children to a
greater degree of drug-induced macrocytosis.
It is postulated that azathioprine-induced
macrocytosis is due to inhibition of DNA synthesis in bone marrow precursor cells, leaving both
RNA and protein synthesis ongoing and leading
to cellular accumulation of nucleic acids.[13] The
difference in individual toxicity may be explained
by genetic polymorphisms of the genes encoding enzymes in thiopurine metabolism.[12] Further studies will be necessary to determine if
this cohort of patients is at increased risk of
malignancies.
This study is limited by its retrospective nature
and population size. Trends could be assessed by
3.0
2.5
Dose (mg/kg)

Indeterminate colitis
Ulcerative colitis
Crohn’s disease

2.0
1.5
1.0
0.5
0
T1

T2

T3

T4

T5

Time period
Fig. 3. Mean dose of azathioprine against time.
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a prospective review, where each patient is monitored over a full 24-month period. In this study,
through a cohort effect, there was a gradual reduction in subject numbers analyzed at each time
interval. A prospective review would allow assessment of the Paediatric Crohn’s Disease Activity
Index, so that trends in hematologic and biochemical parameters could also be correlated with
clinical response. In addition, our graphical analysis gives cumulative data, which might have
masked extremes of leukopenia and macrocytosis.

3. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease:
short- and long-term toxicity. Ann Intern Med 1989; 111:
641-9
4. Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapyrelated cancer. Nat Rev Cancer 2008; 8: 24-36
5. Masunaga Y, Ohno K, Ogawa R. Meta-analysis of risk of
malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother 2007; 41: 21-8
6. Disanti W, Rajapakse RO, Korelitz BI. Incidence of neoplasms in patients who develop sustained leukopenia during
or after treatment with 6-mercaptopurine for inflammatory
bowel disease. Clin Gastroenterol Hepatol 2006; 4: 1025-9
7. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell
lymphoma associated with infliximab use in young patients
treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265-7
8. Bernstein CN, Artinian L, Anton PA, et al. Low-dose
6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity. Dig Dis Sci 1994;
39: 1638-41
9. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease:
a 30 year review. Gut 2002; 50: 485-9
10. Thomas Jr CW, Lowry PW, Franklin CL. Erythrocyte mean
corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients
with inflammatory bowel disease treated with azathioprine
or 6-mercaptopurine. Inflamm Bowel Dis 2003; 9: 237-45
11. Glas J, Torok HP, Daczo J, et al. The leukocyte count predicts the efficacy of treatment with azathioprine in inflammatory bowel disease. Eur J Med Res 2005; 10: 535-8
12. Derijks LJ, Gilissen LP, Hooymans PM. Review article:
thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24: 715-29
13. Al-Safi S, Tashtoush B, Abdul-Razzakl K. Azathioprineinduced fatal macrocytic anemia in rabbits. Pol J Pharmacol 2002; 54: 513-6

Conclusion
Our study has identified that leukopenia generally precedes macrocytosis. Macrocytosis would
therefore not be a good indicator in predicting
onset of leukopenia. Pretreatment factors that are,
as yet, unrecognized may predispose some children
to drug-induced macrocytosis. This could also represent a cohort of children who are at risk of malignancies, necessitating further study.
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